FDA to hold FSIAD meeting

FDA will hold a public meeting Oct. 27 and a scientific workshop Oct. 28 to discuss Female Sexual Interest/Arousal Disorder (FSIAD), and has asked patients for input on therapies to treat the disorder.

FSIAD, the most common form of female sexual dysfunction (FSD), is a combination of hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). There are no approved treatments for FSAD or HSDD. ...